Xeljanz (tofacitinib) is an oral Janus kinase inhibitor used in selected inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, and polyarticular course juvenile idiopathic arthritis in defined populations. The U.S. label carries boxed warnings for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. Initial U.S. approval was in 2012.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Big drug companies said Trump administration pricing deals had little to no noticeable impact on earnings, though details remain confidential. Novo Nordisk and Eli Lilly described bigger effects tied to lower GLP-1 cash-pay prices and expanded Medicare coverage.
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05754710 |
Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis |
RECRUITING |
